境外上市

Search documents
华勤技术:拟发行境外上市股份并在香港联交所上市
Xin Lang Cai Jing· 2025-08-22 08:57
华勤技术公告,2025年 8月 22日,公司召开了董事会和监事会,审议通过了发行境外上市股份(H 股) 并在香港联交所主板上市的相关议案。此举旨在加快公司国际化战略,增强境外融资能力,提高综合竞 争力。具体细节尚未最终确定,需提交股东大会审议,并取得中国证监会、香港联交所和香港证券及期 货事务监察委员会等相关机构的备案、批准和核准。目前,公司正与中介机构商讨发行事宜,但发行能 否成功存在重大不确定性。 ...
利欧股份筹划港股上市有无忽悠成分?实控人遭立案调查 关联交易助力资本运作?
Xin Lang Zheng Quan· 2025-08-22 04:37
Core Viewpoint - Lio Co., Ltd. is facing challenges with weak core business performance and negative cash flow, raising concerns about the quality of its earnings. Additionally, the actual controller of Lio Co., Ltd. is under regulatory investigation, leading to questions about the legitimacy of its planned Hong Kong listing [1][9]. Group 1: Business Performance - Lio Co., Ltd. has a weak core business, primarily relying on investment activities for profitability. The company has been involved in numerous acquisitions, spending over 5 billion yuan on acquiring stakes in more than 20 companies [1]. - The company has two main business segments: mechanical manufacturing and digital marketing. However, its revenue growth has stagnated, with a market share of approximately 3% in the media agency sector, significantly trailing behind the leading competitor, which has a revenue of 20.64 billion yuan [2][3]. - Despite appearing to have substantial revenue, the actual profitability is concerning, with gross profits fluctuating between 1.3 billion yuan and 1.9 billion yuan, leading to a net profit margin of only 200 million to 400 million yuan after accounting for expenses [5][6]. Group 2: Cash Flow and Investment Activities - The company has reported negative cash flow for four consecutive years from 2021 to 2024, raising doubts about the authenticity of its earnings [6]. - Lio Co., Ltd. has shown a keen interest in stock market investments, with plans to use up to 3 billion yuan of its own funds for various securities investments, including new stock subscriptions and bond investments [8]. Group 3: Regulatory Issues - The actual controller of Lio Co., Ltd., Wang Xiangrong, and Vice Chairman Wang Zhuangli are under investigation by the China Securities Regulatory Commission for suspected short-term trading activities involving their mother [9][10]. - The ongoing investigation may pose obstacles to the company's planned overseas listing, as regulatory guidelines prohibit companies with recent legal issues from issuing securities abroad [10]. Group 4: Related Party Transactions - In light of the financial pressures faced by *ST Chuangxing, Lio Co., Ltd. has engaged in related party transactions, raising concerns about potential conflicts of interest and the risk of being financially drained [11][14]. - The company has signed a framework agreement with a related party for construction and engineering services, which it claims will be conducted at fair market prices and will not harm the interests of the company or its shareholders [14].
2800亿“果链巨头”,再冲IPO!
Sou Hu Cai Jing· 2025-08-20 00:41
| | | | 未經審核 | | | | --- | --- | --- | --- | --- | --- | | | | | 截至以下日期止三個月 | | | | | 2025年 | 2024年 | | 2025年 | | | | 6月30日 | 6月30日 | 同比變動 | 3月31日 | 環比變動 | | | | | (人民幣百萬元,除非另有說明) | | | | 收入 | 115.956.1 | 88.887.8 | 30.5% | 111,293.3 | 4.2% | | 毛利 | 26.101.0 | 18.394.2 | 41.9% | 25.405.9 | 2.7% | | 經營利酒 | 13.436.7 | 5.888.7 | 128.2% | 13.125.4 | 2.4% | | 除所得税前利潤 | 14.402.8 | 6.679.4 | 115.6% | 13.168.0 | 9.4% | | 期間利潤 | 11.873.2 | 5.069.7 | 134.2% | 10.892.7 | 9.0% | | 非國際財務報告準則計量: | | | | | | | 經調整淨利潤 | 10 ...
新奥股份赴港上市收证监会反馈:需说明股东穿透信息及股份质押影响等问题
Sou Hu Cai Jing· 2025-08-16 04:50
来源:新浪证券 【相关阅读】 新奥股份招股书解读:营收连续两年下降 净利润降20% 毛利率波动 五、请补充说明你公司从事增值电信业务的三家控股子公司一城一家、好买气及运途云在本次介绍上市 前后的外资股比,本次介绍上市前后你公司及下属子公司是否持续符合外商投资准入政策要求。 六、请补充说明本次拟参与 "全流通" 股东所持股份是否存在被质押、冻结或其他权利瑕疵的情形。 近日,新奥股份收到证监会关于本次境外上市的备案反馈意见,具体反馈如下: 请你公司补充说明以下事项,请律师核查并出具明确的法律意见: 一、请严格对照《监管规则适用指引 —— 第 2 号》补充说明持股 5% 以上股东穿透后的相关信息。 二、请你公司严格对照《境内企业境外发行证券和上市管理试行办法》第八条的规定,补充说明是否存 在境外发行上市禁止性情形。 三、请补充说明你公司控股股东及其一致行动人持有你公司的股份被质押对本次介绍上市的影响。 四、请补充说明你公司两期限制性股票激励计划预留授予的原因。 ...
扬州玺悦收到证监会境外上市备案反馈 需说明股权架构合规性等多项问题
Xin Lang Zheng Quan· 2025-08-16 03:58
Core Viewpoint - The company Yangzhou Xiyue has received feedback from the China Securities Regulatory Commission (CSRC) regarding its overseas listing application, requiring additional clarifications and legal opinions on various aspects of its corporate structure and transactions [1][4]. Group 1: Corporate Structure and Compliance - The company is required to explain the compliance of its equity control structure, including adherence to foreign exchange management, overseas investment, foreign investment, and tax management regulations [1][4]. - Clarification is needed on why Hu Jiahui, the spouse of Xiong Bin, is not recognized as a co-actual controller [1][4]. - A detailed list of the shareholding ratios of pre-restructured shareholders and the issuer must be provided, along with an explanation of any inconsistencies [1][4]. Group 2: Financial Transactions and Related Party Loans - The company must provide background on multiple related party loans provided by Hangzhou Jialin to various entities, including the source of funds and repayment arrangements, to ensure no adverse impact on the upcoming issuance [2]. - The registration capital payment status of domestic entities must be clarified, especially if there are any shortfalls that could affect normal business operations [2]. - The reason for the freezing of 1.8198% equity held by Shandong Jiman Supply Chain Management Co., Ltd. in Hangzhou Zhulin needs to be explained, along with its potential impact on the issuance [2]. Group 3: Business Operations and Data Management - The company is required to self-examine whether its subsidiaries' business activities, such as seed trading and broadcasting, involve prohibited or restricted foreign investment, providing clear evidence of compliance with the negative list of foreign investment access [3]. - Further clarification is needed on whether the company's digital business activities involve the collection and storage of personal user information, and the measures in place for data protection and security [3]. Group 4: Transaction Arrangements for Overseas Listing - The company must detail the specific transaction arrangements for achieving its U.S. listing through a special purpose acquisition company (SPAC), including a list of participating parties and a diagram of the shareholding structure before and after the merger [3].
新股消息 | 新奥股份(600803.SH)拟港股上市 中国证监会要求补充说明持股5%以上股东穿透后的相关信息等
智通财经网· 2025-08-15 13:09
四、请补充说明公司两期限制性股票激励计划预留授予的原因。 五、请补充说明公司从事增值电信业务的三家控股子公司一城一家、好买气及运途云在本次介绍上市前 后的外资股比,本次介绍上市前后公司及下属子公司是否持续符合外商投资准入政策要求。 六、请补充说明本次拟参与"全流通"股东所持股份是否存在被质押、冻结或其他权利瑕疵的情形。 招股书显示,新奥股份是中国最大的民营天然气企业,覆盖天然气全产业链。公司以天然气全场景作为 基础,拥有超过30年的运营实践,庞大坚实的客户基础、丰富的海内外长协资源、中国处理能力最大的 民营LNG接收站、自主研发的风控以及套期保值交易系统,持续深化天然气产业链一体化布局。 智通财经APP获悉,8月15日,中国证监会发布《境外发行上市备案补充材料要求(2025年8月8日—2025 年8月14日)》,证监会国际司共对7家企业出具补充材料要求。在公示中,证监会要求新奥股份补充说 明持股5%以上股东穿透后的相关信息、是否存在境外发行上市禁止性情形等情况。据港交所6月16日披 露,新奥天然气股份有限公司(简称:新奥股份)(600803.SH)向港交所主板递交上市申请,中金公司为其 独家保荐人。 中国证监 ...
美锦能源筹划发行H股股票并在香港联交所上市
Bei Jing Shang Bao· 2025-08-15 13:05
Group 1 - The core point of the article is that Meijin Energy is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and international competitiveness [1] - The company aims to improve its overseas financing capabilities and increase governance transparency and standardization [1] - As of August 15, the stock price of Meijin Energy was reported at 4.59 yuan per share, with a total market capitalization of approximately 20.21 billion yuan [1]
露笑科技: 第六届董事会第十六次会议决议公告
Zheng Quan Zhi Xing· 2025-08-14 16:03
Core Viewpoint - The company plans to issue H shares and list them on the Hong Kong Stock Exchange to enhance its international strategy, attract talent, and improve its financing capabilities [1][2][3] Board Meeting Details - The sixth board meeting was held on August 13, 2025, with all eight directors present, and the meeting complied with relevant laws and regulations [1] - The board unanimously approved the proposal to issue H shares and list them on the Hong Kong Stock Exchange [2][3] Issuance Plan - The H shares will be ordinary shares with a par value of RMB 1.00 each, available for subscription in foreign currency [2] - The issuance will be conducted through a combination of public offering in Hong Kong and international placement [2][5] - The maximum number of H shares to be issued will not exceed 25% of the total share capital post-issuance, with an option for underwriters to exercise an over-allotment of up to 15% [3][4] Fund Utilization - The funds raised will primarily be used for capacity expansion, product development, and repayment of bank loans, among other operational needs [7][8] Shareholder Approval - The proposal requires approval from the shareholders' meeting, and the board is authorized to handle all matters related to the issuance and listing [9][19] Governance Adjustments - The company will revise its articles of association and internal governance rules to align with the requirements of the Hong Kong Stock Exchange and relevant laws [20][29] - The board will also adjust the composition of its committees to meet regulatory standards [27][28] Audit and Compliance - The company has appointed an auditing firm for the issuance process and will ensure compliance with all regulatory requirements [24][25]
利欧股份拟30亿炒股 近4年有3年亏实控人2023收监管函
Zhong Guo Jing Ji Wang· 2025-08-11 05:49
中国经济网北京8月11日讯利欧股份(002131)(002131.SZ)近日发布关于进行证券投资的公告显示,公司于8月8日召 开第七届董事会第十二次会议,会议审议通过了《关于使用自有资金进行证券投资的议案》,同意公司及下属子公 司使用最高额度不超过30亿元人民币(或投资时点等值外币)的自有资金进行证券投资。该议案无需提交股东大会审 议,授权期限自本次董事会审议通过之日起12个月内有效。 公告显示,投资方式包括新股配售或者申购、股票及存托凭证投资、债券投资、委托理财以及深圳证券交易所认定 的其他投资行为。其中,委托理财是指公司委托银行、信托、证券、基金、期货、保险资产管理机构、金融资产投 资公司、私募基金管理人等专业理财机构对其财产进行投资和管理或者购买相关理财产品(不包括公司于2025年4月 29日公布的《关于使用部分闲置自有资金进行现金管理的公告》中涉及的投资品种)的行为。 授权董事长选择合适人选成立证券投资领导小组,负责公司证券投资的决策与实施等各项工作。 | | 2023 年 | 2022 年 | | 本年比上年 增减 | 2021 年 | | | --- | --- | --- | --- | --- ...
可孚医疗筹划发行H股股票并在香港联交所上市
Bei Jing Shang Bao· 2025-08-10 03:37
Core Viewpoint - The company, Kewei Medical, has announced its plan to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [1] Group 1: Company Actions - Kewei Medical held its 16th board meeting and 15th supervisory meeting on August 7, where it approved the proposal for issuing H-shares and listing on the Hong Kong Stock Exchange [1] - The company aims to accelerate its global strategy and improve its overseas business development capabilities through this listing [1] Group 2: Strategic Intent - The issuance of H-shares is intended to enhance the company's brand image and recognition in international markets [1] - The company will consider the interests of existing shareholders and the conditions of domestic and foreign capital markets when determining the timing and window for the issuance [1]